N-(4-aminophenyl)-4-chlorobenzenesulfonamide | 313553-78-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-aminophenyl)-4-chlorobenzenesulfonamide
• CAS: 313553-78-5
• 化学式: C₁₂H₁₁ClN₂O₂S
• mdl: MFCD00222919
• 分子量: 282.751
• InChiKey: ZEXMYNXHUJMAQE-UHFFFAOYSA-N

物化性质

• 熔点：
  170-171 °C(Solv: ethyl acetate (141-78-6); cyclohexane (110-82-7))
• 沸点：
  468.8±55.0 °C(Predicted)
• 密度：
  1.466±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-aminophenyl)-4-chlorobenzenesulfonamide 、 3,5-双三氟甲基苯甲醛 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 以80%的产率得到N-(4-((3,5-bis(trifluoromethyl)benzyl)amino)phenyl)-4-chlorobenzenesulfonamide
  参考文献：
  名称：

  In vitro PAI-1 inhibitory activity of oxalamide derivatives☆

  摘要：

  A number of oxalamide derivatives have been synthesized and evaluated for PAI-1 inhibitory activity. In vitro PAI-1 inhibitory activities of oxalamide derivatives are evaluated by chromogenic assay. Few compounds have shown significant PAI-1 inhibitory activity. (c) 2007 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2007.05.011
• 作为产物：
  描述：

  4-硝基苯胺 在 吡啶 、 铁粉 、 氯化铵 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 生成 N-(4-aminophenyl)-4-chlorobenzenesulfonamide
  参考文献：
  名称：

  N-(4-acetamidophenyl)-5-acetylfuran-2-carboxamide as a novel orally available diuretic that targets urea transporters with improved PD and PK properties

  摘要：

  DOI：

  10.1016/j.ejmech.2021.113859

文献信息

• N-substituted benzenesulfonamide compounds: DNA binding properties and molecular docking studies
  作者：Seyit Ali Güngör、Mehmet Tümer、Muhammet Köse、Sultan Erkan

  DOI：10.1080/07391102.2021.1897683

  日期：2022.11.2

  imine compounds 5–8 were prepared and screened for their binding properties to the FSdsDNA. The structures of synthesized compounds were elucidated by the spectroscopic and analytical methods. Compounds 5–8 were screened for their interactions with the FSdsDNA. Compound 8 showed the highest binding affinity to the FSdsDNA with intrinsic binding constant of 3.10 × 104 M−1. The compounds caused the quenching

  抽象的 制备苯磺酰胺基亚胺化合物5 – 8 ，并筛选其与 FSdsDNA 的结合特性。通过光谱和分析方法阐明了合成化合物的结构。筛选了化合物5 – 8与 FSdsDNA 的相互作用。化合物8对FSdsDNA表现出最高的结合亲和力，内在结合常数为3.10×10 4 M -1 。这些化合物导致 DNA-EB 发射猝灭，表明 FSdsDNA 中 EB（溴化乙锭）被置换。最后，通过分子对接研究检查了 DNA 和结合分子5-8之间的结合相互作用。这些化合物通过磺酰胺氧原子和 DNA 的 DG10/DG16 核苷酸之间的氢键接触，定位在 DNA 小沟的大致相同区域。 拉马斯瓦米·萨尔马 (Ramaswamy H. Sarma) 通讯
• Synthesis, characterization and docking studies of benzenesulfonamide derivatives containing 1,2,3-triazole as potential ınhibitor of carbonic anhydrase I-II enzymes
  作者：Seyit Ali Güngör、Muhammet Köse、Mehmet Tümer、Cüneyt Türkeş、Şükrü Beydemir

  DOI：10.1080/07391102.2022.2159531

  日期：——

  Carbonic Anhydrases (CAs) are an important family of metalloenzymes that contain zinc (Zn2+) ions in their active site and catalyze the conversion of carbon dioxide to bicarbonate and proton and fo...

  碳酸酐酶 (CA) 是一个重要的金属酶家族，其活性位点含有锌 (Zn2+) 离子，可催化二氧化碳转化为碳酸氢盐和质子，并产生...
• Analgesic agents without gastric damage: Design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors
  作者：Xiaoxia Zheng、Hiroyuki Oda、Kayo Takamatsu、Yukio Sugimoto、Akihiro Tai、Eiichi Akaho、Hamed Ismail Ali、Toshiyuki Oshiki、Hiroki Kakuta、Kenji Sasaki

  DOI：10.1016/j.bmc.2006.10.029

  日期：2007.1

  In order to create novel analgesic agents without gastric disturbance, structurally simple cyclooxygenase-1 (COX-1) inhibitors with a benzenesulfonanilide skeleton were designed and synthesized. As a result, compounds 11f and 15a, which possess a p-amino group on the benzenesulfonyl moiety and p-chloro group on the anilino moiety, showed COX-1-selective inhibition. Moreover compound 11f, which is the most potent compound in this study showed more potent analgesic activity than that of aspirin at 30 mg/kg by po. The anti-inflammatory activity and gastric damage, however, were very weak or not detectably different from aspirin. Since the structure of our COX-1 inhibitors are very simple, they may be useful as lead compounds for superior COX-1 inhibitors as analgesic agents without gastric disturbance. (c) 2006 Published by Elsevier Ltd.